Home-administered transcranial direct current stimulation is a feasible intervention for depression: an observational cohort study

Frontiers in Psychiatry

Psychiatry

Marom Bikson¹  Erik Charlson²  Amy Vogel-Eyny²  Hyein Cho²  Giuseppina Pilloni²  Matthew Lustberg²  Leigh Charvet²  Allan George²  Luis Fernandez²  Pamela Best²  Kamran Nazim³  Abhishek Datta⁴  Tehila Eilam-Stock⁵ 

[1] Department of Biomedical Engineering, The City College of New York, New York, NY, United States;Department of Neurology, New York University Grossman School of Medicine, New York, NY, United States;Research and Development, Soterix Medical, Inc., Woodbridge Township, NJ, United States;Research and Development, Soterix Medical, Inc., Woodbridge Township, NJ, United States;Department of Biomedical Engineering, The City College of New York, New York, NY, United States;The Arthur S. Abramson Department of Rehabilitation Medicine, Albert Einstein College of Medicine, New York, NY, United States;

关键词: depression;    non-invasive brain stimulation;    telehealth;    home-based tDCS;    digital health;    transcranial direct current stimulation (tDCS);    major depressive disorder;   

DOI  :  10.3389/fpsyt.2023.1199773

 received in 2023-04-04, accepted in 2023-07-25,  发布年份 2023

来源: Frontiers

【 摘 要 】

Transcranial direct current stimulation (tDCS) is an emerging treatment for major depression. We recruited participants with moderate-to-severe major depressive episodes for an observational clinical trial using Soterix Medical's tDCS telehealth platform as a standard of care. The acute intervention consisted of 28 sessions (5 sessions/week, 6 weeks) of the left anodal dorsolateral prefrontal cortex (DLPFC) tDCS (2.0 mA × 30 min) followed by a tapering phase of weekly sessions for 4 weeks (weeks 7–10). The n = 16 completing participants had a significant reduction in depressive symptoms by week 2 of treatment [Montgomery–Åsberg Depression Rating Scale (MADRS), Baseline: 28.00 ± 4.35 vs. Week 2: 17.12 ± 5.32, p < 0.001] with continual improvement across each biweekly timepoint. Acute intervention responder and remission rates were 75 and 63% and 88 and 81% following the taper period (week 10).

【 授权许可】

Unknown   
Copyright © 2023 Charvet, George, Charlson, Lustberg, Vogel-Eyny, Eilam-Stock, Cho, Best, Fernandez, Datta, Bikson, Nazim and Pilloni.